Completed studies Data updated 24 Nov 2016
No Study Name/Phase Type Sponsor Enrolled. (Retention rate) Period
1 Carraguard/Phase III Microbicide PC 2402 (86%) 2004-2007
2 FEM PreP/Phase III Oral Prep FHI360 764 (87.5%) 2009-2012
3 ACASI/Phase II Behavioral PC 200 (100%) 2007
4 SBC preparedness /Phase III Mapping FHI360 >1000 2009-2012
5 HSV 2/Phase III HSV2 Treatment Norvartis 8 2008-2009
6 Diabetic Peripheral Neuropathic/Phase III Observational Pfizer 8 (100%) 2011
7 Tyrosur study/Phase III Wound Healing Engelhard Arzneimittel 55 (100%) 2012-2013
8 Impetigo/Phase III Impetigo Treatment Galderma Inc 49 (100%) 2012-2013
9 PrEP & Risk Compensation/Phase III Behavioral FHI 360 540 (100%) 2012-2013
10 PreP & Adherence /Phase III Behavioral FHI 360 229 (100%) 2013
11 TESEC 05/Phase III TB Diagnostic Statens Serum Institut 164 (98.8%) 2012-2013
12 TESEC 07/Phase II/III TB Diagnostic Statens Serum Institut 64 (99%) 2012-2013
13 FACTS 001/Phase III Microbicide CONRAD 460 (89%) 2011-2015
14  Group B streptococcus/Phase III Observational Norvatis 501 2013-2015
15 CE/049/ACT/Phase IV Wound Healing Smith & Nephew 12 (100%) 2015